ASCLETIS-B(01672): Ascletis to Present Research Results for Oral Small-Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Agonist Peptide ASC37 at ObesityWeek 2026
ASCLETIS-B (01672) announced that two posters on its obesity pipelinethe oral small-molecule GIPR agonist ASC48 and the GLP-1R/GIPR/GCGR triple agonist peptide ASC37will be presented at ObesityWeek 2026. The conference will be held from November 14 to 17, 2026, in Washington, D.C., USA.
ASCLETIS-B (01672) announced that two posters on its obesity pipelinethe oral small-molecule GIPR agonist ASC48 and the GLP-1R/GIPR/GCGR triple agonist peptide ASC37will be presented at ObesityWeek 2026. The conference will be held in Washington, D.C., USA, from November 14 to 17, 2026.
"We are pleased to present the latest preclinical progress from our robust and highly differentiated small-molecule and peptide obesity pipeline at ObesityWeek 2026," said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. "These advances reflect our strong commitment to developing highly differentiated treatment options for obesity."
Related Articles
ANTENGENE-B (06996) repurchased 108,000 shares on November 2 for approximately HK$303,600.
MNSO (09896) repurchased 11,200 shares on November 2 for HK$223,700.
PRU (02378) repurchased approximately 427,400 shares for about GBP3.9524 million on October 30.
ANTENGENE-B (06996) repurchased 108,000 shares on November 2 for approximately HK$303,600.
MNSO (09896) repurchased 11,200 shares on November 2 for HK$223,700.
PRU (02378) repurchased approximately 427,400 shares for about GBP3.9524 million on October 30.
